The present invention is directed to compounds of Formulae (I), (IIa-IIh), (IIIa-IIIe), (IVa-IVc), (Va-V1), (VIa-VII), (VII), (VIII) and (IX), pharmaceutical compositions thereof and methods of use thereof in the treatment of conditions associated with a dysfunction in proteostasis.
Condensed cyclic compound and organic light-emitting device including the same
申请人:SAMSUNG ELECTRONICS CO., LTD.
公开号:US10873034B2
公开(公告)日:2020-12-22
A condensed cyclic compound represented by Formula 1:
Ar1-(L1)a1-Ar2 Formula 1
wherein, in Formula 1, Ar1, Ar2, L1, and a1 are the same as described in the specification.
Sangapure,S.S.; Agasimundin,Y.S., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1978, vol. 16, p. 627 - 629
作者:Sangapure,S.S.、Agasimundin,Y.S.
DOI:——
日期:——
Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof
申请人:Verkman Alan
公开号:US20070265316A1
公开(公告)日:2007-11-15
The invention provides compositions, pharmaceutical preparations and methods for activation of the ΔF508 cystic fibrosis transmembrane conductance regulator protein (ΔF508 CFTR) that are useful for the treatment and study of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more tetrahydrobenzothiophene, benzofuran, pyramidinetrione, dihydropyridine, tetraahydrocarbazol or anthraquinone compounds (referred to as “activator compounds”). The invention provides methods increasing ion transport in a ΔF508 CFTR in a cell by contacting the cell with an effective amount of an activator compound. In other embodiments, the invention also provides a method of treating a patient suffering from a ΔF508 CFTR-mediated disease or condition, for example CF, by administering to the patient an efficacious amount of an activator compound. Kits for use in the subject methods are also provided.